Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew L Hemming

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
British Journal of Cancer|September 29, 2022
Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GISTInga-Marie Schaefer, Matthew L Hemming, Meijun Z Lundberg, et al.
Nature Medicine|May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trialPriscilla Merriam, James J Morrow, Emanuele Mazzola, et al.
International Journal of Cancer|November 1, 2021
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation studySophie Cousin, Jean-Yves Blay, Irene Braña Garcia, et al.
Blood|February 28, 2022
BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomesMichael C Zaiken, Ryan Flynn, Katelyn G Paz, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
British Journal of Cancer|September 29, 2022
Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GISTInga-Marie Schaefer, Matthew L Hemming, Meijun Z Lundberg, et al.
Nature Medicine|May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trialPriscilla Merriam, James J Morrow, Emanuele Mazzola, et al.
International Journal of Cancer|November 1, 2021
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation studySophie Cousin, Jean-Yves Blay, Irene Braña Garcia, et al.
Blood|February 28, 2022
BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomesMichael C Zaiken, Ryan Flynn, Katelyn G Paz, et al.
Pageof 3